Global Graves' Disease (Overactive Thyroid) Market – Industry Trends and Forecast to 2029

Global Graves' Disease (Overactive Thyroid) Market, By Diagnosis (Radioactive Iodine Uptake, Imaging Tests, Blood Tests, Others), Treatment (Radioactive iodine therapy, Medication, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Market Analysis and Size

Graves' disease is an immune system condition characterized by excessive thyroid hormone production (hyperthyroidism). Graves' disease is a common cause of hyperthyroidism, though a variety of conditions can cause it. Graves' disease has a wide range of signs and symptoms because thyroid hormones affect many different body systems. Graves' disease can affect anyone, however it is more common in women and those under the age of 40.

Data Bridge Market Research analyses that the Graves' disease (overactive thyroid) market was valued at USD 351.55 million in 2021 and is expected to reach USD 507.65 million by 2029, registering a CAGR of 4.70% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Market Definition

Graves' disease (overactive thyroid), sometimes known as Basedow's disease, is an autoimmune condition that leads to hyperthyroidism. It occurs when the body's immune cells attack the thyroid, causing excessive thyroid hormone production. Graves' disease treatment aims to inhibit thyroid hormone production and block the hormones' effects on the body. Beta-blockers including propranolol and metoprolol are frequently used as first-line treatments. These medications help to keep your heart rate in check and safeguard it until other hyperthyroidism treatments take effect. Antithyroid drugs like methimazole (Tapazole) and propylthiouracil stop the thyroid gland from producing thyroid hormone. Radioiodine therapy entails taking a single dose of radioactive iodine in the form of a pill or a liquid. Radiation kills thyroid gland cells over a period of two to three months.

Graves' Disease (Overactive Thyroid) Market Dynamics

Drivers

• Increasing prevalence of Graves' disease (overactive thyroid)

The rising prevalence of Graves' disease (overactive thyroid) across the globe is estimated to enhance the market's growth. Hyperthyroidism has a number of dangerous side effects, including cardiac problems. A high heart rate, atrial fibrillation (a heart rhythm disease that raises your risk of stroke), and congestive heart failure (a condition in which your heart can't pump enough blood to satisfy your body's needs) are all symptoms.

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of Graves' disease (overactive thyroid) market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Changing lifestyle of people

The changing lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of Graves' disease (overactive thyroid) market. Graves' disease is worsened by cigarette smoking, weakening the immune system. Smokers with Graves' illness are more likely to develop Graves' ophthalmopathy.

Furthermore, rising initiatives by public and private organizations to spread awareness and increasing incidences of autoimmune diseases such as diabetes and others will expand the Graves' disease (overactive thyroid) market. Additionally, rising level of disposable income and surging geriatric population are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the Graves' disease (overactive thyroid) market growth. 

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the Graves' disease (overactive thyroid) market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the Graves' disease (overactive thyroid) market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This Graves' disease (overactive thyroid) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Graves' disease (overactive thyroid) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Graves' disease is more common in women as compared to men. It mainly affects adults between the ages of 30 and 50. Graves' disease affects one in every 200 people in the United States, making it the most common cause of hyperthyroidism.

Graves' disease (overactive thyroid) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Graves' Disease (Overactive Thyroid) Market Scope

The Graves' disease (overactive thyroid) market is segmented on the basis of treatment, diagnosis, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Radioactive iodine therapy
• Medication
• Corticosteroids
• Beta-blockers
• Propranolol
• Atenolol
• Metoprolol
• Nadolol

Anti-thyroid medications

• Propylthiouracil
• Methimazole
• Others

Diagnosis

• Radioactive Iodine Uptake
• Imaging Tests
• CT scan
• Ultrasound
• Magnetic resonance imaging (MRI)
• Others
• Blood Tests
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Graves' Disease (Overactive Thyroid) Market Regional Analysis/Insights

The Graves' disease (overactive thyroid) market is analysed and market size insights and trends are provided by country, treatment, diagnosis, route of administration, end-users and distribution channel as referenced above.

The countries covered in the Graves' disease (overactive thyroid) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the Graves' disease (overactive thyroid) market because of the rising prevalence of Graves' disease (overactive thyroid) and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and the presence of major key players will further propel the market's growth rate.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to the increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Graves' Disease (Overactive Thyroid) Market Share Analysis

The Graves' disease (overactive thyroid) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to Graves' disease (overactive thyroid) market.

Some of the major players operating in the Graves' disease (overactive thyroid) market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Hikma Pharmaceuticals PLC (U.K.)
• Bristol-Myers Squibb Company (U.S.)
• Bayer AG (Germany)
• Boehringer Ingelheim International GmbH. (Germany)
• Dr. Reddy's Laboratories Ltd. (India)
• Gilead Sciences, Inc. (U.S.)
• Amgen Inc. (U.S.)
• Eli Lilly and Company (U.S.)
• AbbVie Inc. (U.S.)
• Lupin (India)
• Allergan (Ireland)